24 C
New York
Wednesday, June 3, 2026

Tag: clinic

New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction

Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....

Hydreight Announces Refiling of Interim Financial Statements

VANCOUVER, BC and LAS VEGAS, June 2, 2026 /CNW/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a...

Mayo Clinic and Microsoft collaborate to develop a frontier AI model for healthcare

Collaboration aims to expand access to Mayo Clinic's trusted healthcare expertise and improve patient and clinician experiences   ROCHESTER, Minn., and REDMOND, Wash., June 2, 2026 /PRNewswire/...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working...

Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /CNW/ - Hydreight...

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL

INVO Fertility Announces Second Quarter 2025 Financial Results

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.

Tecan issues CHF 150 million straight bond

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may...

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinic